Clinical Trial

Efficacy and Safety of AG2001 in Patients With Acute Bronchitis

Study acronym: AG2001 P3
Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated September 30, 2025 (before its estimated March 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a Phase 3, randomized, double-blind, active-controlled clinical trial designed to evaluate the efficacy and safety of AG2001 in patients with acute bronchitis. The primary objective is to demonstrate the superiority of AG2001 over two active comparators based on the change in Bronchitis Severity Score (BSS) at Day 4.
Trial Details
NCT Number NCT07198347
Lead Sponsor Ahn-Gook Pharmaceuticals Co.,Ltd
Conditions Acute Bronchitis
Enrollment 300 participants
Start Date 2025-11-01
Primary Completion 2026-03-31 (estimated)
Study Completion 2026-10-31 (estimated)
Updated on ClinicalTrials.gov 2025-09-30